1. Desmopressin use in major cardiac surgery is associated with renal impairment: a retrospective single-center analysis.
- Author
-
Koköfer, Andreas, Rodemund, Niklas, Cozowicz, Crispiana, Stundner, Ottokar, Fischer, Lukas, and Wernly, Bernhard
- Subjects
- *
RISK assessment , *THERAPEUTICS , *RENAL replacement therapy , *LOGISTIC regression analysis , *ACUTE kidney failure , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *HEMODYNAMICS , *HOSPITAL mortality , *DESMOPRESSIN , *LONGITUDINAL method , *SURGICAL complications , *ODDS ratio , *ELECTIVE surgery , *LACTATES , *VASOCONSTRICTORS , *BLOOD transfusion , *CONFIDENCE intervals , *CARDIAC surgery , *DISEASE risk factors - Abstract
Background: Desmopressin acetate (1-deamino-8-d-arginine vasopressin—DDAVP) is a analogue of the antidiuretic hormone vasopressin. DDAVP is suggested to reduce bleeding after cardiac surgery using cardiopulmonary bypass. The aim of this study was to determine if DDAVP has any negative impact on renal function leading to acute kidney injury (AKI) and therefore increases the need for renal replacement therapy (RRT). Methods: We performed a retrospective single institutional cohort analysis of 2,179 patients undergoing elective and urgent cardiac surgery with CPB from 2017 to 2021. Logistic regression analysis was used to investigate any association between DDAVP, the incidence of AKI KDIGO class 3 and the need for RRT, respectively. The model was adjusted for relevant covariates, including preexisting renal impairment, pharmacological hemodynamic support with vasopressors, complexity of the surgery and postoperative lactate. Secondary outcomes included, in hospital mortality and the need for allogenic blood transfusion. Results: A total of 992 (45.5%) patients received DDAVP intraoperatively during surgery or shortly thereafter. The use of DDAVP was associated with a significant increase in in AKI KDIGO class 3 (OR 2.27; 95% CI 1.46–3.55; p < 0,001) and the need for RRT (OR 2.19; 95%CI 1.48–3.24; p < 0,001). Both findings persisted after covariate adjusting. No increased in-hospital mortality was associated with DDAVP. Conclusion: In cardiac surgery, the use of DDAVP was associated with an increased rate of server AKI and the requirement for RRT. Given the severity of the potential harm associated with DDAVP, an evidence-based reevaluation is needed to enable an accurate risk and benefit assessment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF